NEW YORK (GenomeWeb) – DermTech, a private developer of gene expression-based tests for skin diseases, announced today that it has formed a sales and marketing collaboration with Dermpath Diagnostics.

Under the terms of the deal, Dermpath — a Quest Diagnostics-owned dermatopathology services provider — will provide specialty dermatology representatives in up to 10 regional territories across the US to help DermTech in marketing its Pigmented Lesion assay (PLA), which analyzes the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.